发明名称 |
METHODS AND MATERIALS FOR PREDICTING RESPONSE TO NIRAPARIB |
摘要 |
This document provides methods and materials involved in assessing samples (e.g., cancer cells) for the presence of homologous recombination deficiency (HRD) or an HRD signature to predict response to niraparib. For example, methods and materials for determining whether or not a cell (e.g., a cancer cell) contains an HRD signature to predict response to niraparib are provided. |
申请公布号 |
US2016160294(A1) |
申请公布日期 |
2016.06.09 |
申请号 |
US201514962588 |
申请日期 |
2015.12.08 |
申请人 |
Tesaro ;Myriad Genetics, Inc. |
发明人 |
Wilcoxen Keith;Gutin Alexander;Timms Kirsten;Abkevich Victor;Wang Yan;Lanchbury Jerry |
分类号 |
C12Q1/68;A61K31/454 |
主分类号 |
C12Q1/68 |
代理机构 |
|
代理人 |
|
主权项 |
1. An in vitro method of predicting patient response to a cancer treatment regimen comprising niraparib, the method comprising:
(1) determining in a patient sample the number of Indicator CA Regions comprising at least two types chosen from Indicator LOH Regions, Indicator TAI Regions, or Indicator LST Regions in at least two pairs of human chromosomes of a breast cancer cell; and (2) diagnosing a patient in whose sample said number of Indicator LOH Regions, Indicator TAI Regions, and/or Indicator LST Regions is greater than a reference number as having an increased likelihood of responding to said cancer treatment regimen. |
地址 |
Waltham MA US |